TITLE:
Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
AUTHORS:
Lamyae Nouiakh, Karima Oualla, Imane Ouafki, Soumia Berrad, Hayat Erraichi, Lamiae Amaadour, Zineb Benbrahim, Samia Arifi, Nawfel Mellas
KEYWORDS:
Tyrosine Kinase Inhibitors, Safety, Side Effects
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.12 No.3,
March
12,
2021
ABSTRACT: Tyrosine kinase inhibitors (TKIs) have become a prominent option in the
therapeutic arsenal of several cancers. The safety of these drugs has shown
various toxicities with varying frequency and severity between different
agents. The aim of this study is to
describe the safety profile of different classes of TKI used in various solid
tumors. It is a retrospectively descriptive study conducted in the Department of Medical Oncology at
Hassan II University Hospital of Fez, Morocco, over
a period of 6 years from April 2013 until April 2019. It included 216
patients who received one or more TKI for different indications in solid
tumors. The average age in our series was 61.4 years with a sex ratio F/M of
1.07. Among the most used TKIs in our department according
to their availability: Imatinib (32%) and sunitinib (32%). All patients
received one or more tyrosine kinase inhibitors according to the indication.
Kidney cancer was the most common malignancy (36%), followed by
gastrointestinal stromal tumors (33%). The median duration of treatment was 15
months with extremes of 1 month and 102 months. The main side effects were:
Cutaneous in 43% of patients. Digestive toxicity occurred in 36% of cases. Hematotoxicity
was reported in 33% of cases. The safety profile of TKIs used in our study was
comparable to their global tolerance reported in literature. More studies are needed to investigate the relationship
between their toxicity and their efficacy in Moroccan population.